CSF1R and neoplasm: By inhibiting key kinases involved in angiogenesis, oncogenesis and tumor immunity, such as vascular endothelial growth factor receptors (VEGFRs), tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 (TIE2), KIT, RET, RAF1, BRAF, platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptors (FGFRs) and colony-stimulating factor-1 receptor (CSF-1R) [10, 12], regorafenib exerts a broad-spectrum anti-cancer effect.